---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-220721"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2025-09-26T23:59:59+00:00"
generated_at: "2026-05-17T05:35:59.366601+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics shareholders approve 24.18M share increase and Series B conversion at less than minimum price

## Summary
- Shareholders approved increasing plan shares by 24,180,000 to 31,932,466 total; evergreen cap raised to 73,750,000 shares.
- Approved issuance of over 19.99% of outstanding common stock upon Series B Preferred conversion at less than Nasdaq minimum price, deemed a potential change of control.
- Proposal 1 (conversion) passed with 5,502,026 votes for, 515,275 against, 35,744 abstentions.
- Proposal 2 (plan amendment) passed with 5,089,862 votes for, 951,598 against, 11,585 abstentions.
- Approximately 54.5% of outstanding shares were present, forming a quorum.

## SEC filing metadata
- accession: 0001193125-25-220721
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2025-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000119312525220721/0001193125-25-220721-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000119312525220721/sabs-20250926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-220721
- JSON: https://secwatch.observer/filing/0001193125-25-220721.json
- Plain text: https://secwatch.observer/filing/0001193125-25-220721.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.